Gilead HCV Sales Plateau, But Maintain Dominant Market Share
This article was originally published in The Pink Sheet Daily
Executive Summary
Harvoni sales decline for the second straight quarter in the US due to several factors, but new markets coming online in Europe and early growth in Japan provide some offset.